By Michelle Starr | Science Alert
Rats afflicted with liver cancer have demonstrated the efficacy of a fascinating, non-invasive treatment.
Using focused ultrasound, scientists have managed to destroy up to 75% of the volume of a liver tumour. The treatment also seems to trigger the rats’ immune systems into taking over and clearing the rest.
In 80% of the animals, the cancer seemed to be destroyed, with no sign of metastases or recurrence in the three months they were monitored for, the researchers said.
The treatment, called histotripsy, is currently being trialed in humans with liver cancer.
“Histotripsy is a promising option that can overcome the limitations of currently available ablation modalities and provide safe and effective non-invasive liver tumour ablation,” said biomedical engineer Tejaswi Worlikar of the University of Michigan.
“We hope that our learnings from this study will motivate future preclinical and clinical histotripsy investigations toward the ultimate goal of clinical adoption of histotripsy treatment for liver cancer patients.”
Developed and pioneered at the University of Michigan, histotripsy seems to offer new hope for patients with one of the deadliest forms of cancer: the five-year survival rate for liver cancer is currently lower than 18% in the US.
The technique employs an ultrasound transducer, not for bouncing off internal structures for imaging purposes, but to physically disrupt cancerous tumours.
The way it works is by ultrasound cavitation – similar to the method used to non-invasively break down fat cells for weight-loss treatments. Waves of ultrasound are directed at the area to be treated; the vibrations generate tiny bubbles in the targeted tissue. When the bubbles collapse, or burst, the tissue is disrupted, destroying that part of the tumour.
It’s not often possible to target the entire tumour. The way the masses are positioned, their size and their stage can all influence whether it’s safe to use histotripsy on the entire tumour.
But even partial treatment resulted in complete regression in 81% of the rats treated, the researchers found. By contrast, 100% of the control rats showed tumour progression.
“Our transducer, designed and built at [University of Michigan], delivers high amplitude microsecond-length ultrasound pulses – acoustic cavitation – to focus on the tumour specifically to break it up,” said biomedical engineer Zhen Xu of the University of Michigan.
“Even if we don’t target the entire tumour, we can still cause the tumour to regress and also reduce the risk of future metastasis.”
For the purpose of this study, 22 lab rats were implanted with liver cancer. Half were left as a control group, while the remaining 11 were treated using histotripsy, targeting between 50 and 75% of the tumour volume.
An additional three rats were treated to a lesser extent, with the histotripsy targeting just 25% of the tumour volume.
Following treatment, the rats were euthanized and dissected to determine how successful the treatment had been. The researchers looked for signs of progression, metastasis, and immune markers.
The prognosis for the control rats was dire. All 11 showed signs of progression and metastasis. Within three weeks, the tumours reached the maximum size allowed by ethical protocols and the animals were euthanized.
But the treated rats fared much, much better. Not only did the treatment proceed without complication or side effects, the majority of the rats – nine of the 11 – showed tumour regression, and experienced tumour-free survival for the remainder of the study, around 10 weeks.
Previous histotripsy studies had demonstrated that the treatment is effective at reducing tumour volume. The new work shows that it seems to significantly increase survival rates post-treatment, too.
“This study demonstrated the potential of histotripsy for successful non-invasive tumour ablation, and prevention of local tumour progression and metastasis. Even with partial ablation, complete local tumour regression was observed in 9 of 11 treatment rats, with no recurrence or metastasis up to the 12-week study endpoint, as evidenced by MRI and histology,” the researchers wrote in their paper.
“These results suggest that histotripsy may not increase the risk of developing metastases post-ablation, as compared to controls. Future studies will continue to investigate the safety, efficacy, and biological effects of histotripsy, for potential translation to clinic.”
The research has been published in Cancers.
* * *